Onconova Therapeutics Inc. (ONTX)

Two Narazaciclib Studies To Be Presented At AACR Meeting


Robert LeBoyerMedia Inquiries
Senior Life Sciences Analyst
March 16, 2023
Report ID: 25691
Get Report
Refer to the full report for the price target, fundamental analysis, and rating.

Equity Research provided by Noble Capital Markets is available at no cost to Registered users of Channelchek.

Already Registered? Click the ‘Get Report’ button to login and view the research report.

Not a Member? Click ‘Join’ or ‘Get Report’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.


Onconova Therapeutics Inc.
Onconova Therapeutics Inc.
Healthcare
Biotechnology
Ticker
ONTX
Current Price
$1.18 -1.67%
Market Cap
$24.7M
Price Target
Refer to Report
Volume
57.9K
52wk Range
$0.62 - $1.52
Related Research Reports
5/16/2023

1Q23 Reported With Clinical Progress Review
1Q23 Reported With Clinical Progress Review (ONTX)
4/20/2023

Data Presented on Narazaciclib Targets and Mechanisms
Data Presented on Narazaciclib Targets and Mechanisms (ONTX)
3/17/2023

FY2022 Reported With Two New Trials About To Begin
FY2022 Reported With Two New Trials About To Begin (ONTX)
3/16/2023

Two Narazaciclib Studies To Be Presented At AACR Meeting
Two Narazaciclib Studies To Be Presented At AACR Meeting (ONTX)

Inbox Intel from Channelchek.

Informed investors make more money. And it’s all about timing. Get it when it happens.

By clicking submit you are agreeing to the Terms of Use and Privacy Policy
© 2018-2023 Noble Financial Group, Inc. All Rights Reserved. Channelchek is provided at no cost to be used for information purposes only and not as investment advisement.